When rectal cancer occurs below the pectinate line, it has the potential to spread to the superficial inguinal lymph nodes. Conversely, if the cancer is located above the line, it may spread to the internal iliac lymph nodes. Additionally, the internal iliac and sacral nodes can receive drainage from various regions including the rectum, perineum, cervix, and prostate.

Lymphatic drainage is the process by which lymphatic vessels carry lymph, a clear fluid containing white blood cells, away from tissues and organs and towards lymph nodes. The lymphatic vessels that drain the skin and follow venous drainage are called superficial lymphatic vessels, while those that drain internal organs and structures follow the arteries and are called deep lymphatic vessels. These vessels eventually lead to lymph nodes, which filter and remove harmful substances from the lymph before it is returned to the bloodstream.

The lymphatic system is divided into two main ducts: the right lymphatic duct and the thoracic duct. The right lymphatic duct drains the right side of the head and right arm, while the thoracic duct drains everything else. Both ducts eventually drain into the venous system.

Different areas of the body have specific primary lymph node drainage sites. For example, the superficial inguinal lymph nodes drain the anal canal below the pectinate line, perineum, skin of the thigh, penis, scrotum, and vagina. The deep inguinal lymph nodes drain the glans penis, while the para-aortic lymph nodes drain the testes, ovaries, kidney, and adrenal gland. The axillary lymph nodes drain the lateral breast and upper limb, while the internal iliac lymph nodes drain the anal canal above the pectinate line, lower part of the rectum, and pelvic structures including the cervix and inferior part of the uterus. The superior mesenteric lymph nodes drain the duodenum and jejunum, while the inferior mesenteric lymph nodes drain the descending colon, sigmoid colon, and upper part of the rectum. Finally, the coeliac lymph nodes drain the stomach.

Cyclophosphamide is a medication that is used to treat various types of cancer and induce immunosuppression in patients before stem cell transplantation. It works by causing cross-linking in DNA. However, one of the complications of cyclophosphamide treatment is haemorrhagic cystitis. This occurs because when the liver breaks down cyclophosphamide, it releases a toxic metabolite called acrolein. Acrolein is concentrated in the bladder and triggers an inflammatory response that can lead to haemorrhagic cystitis.

To reduce the risk of haemorrhagic cystitis, doctors can administer MESNA, a drug that conjugates acrolein and reduces the inflammatory response.

Bleomycin, on the other hand, degrades preformed DNA instead of causing cross-linking. Hydroxyurea inhibits ribonucleotide reductase, which decreases DNA synthesis. 5-Fluorouracil (5-FU) is a pyrimidine analogue that arrests the cell cycle and induces apoptosis. Vincristine inhibits the formation of microtubules.

Cytotoxic agents are drugs that are used to kill cancer cells. There are several types of cytotoxic agents, each with their own mechanism of action and potential adverse effects. Alkylating agents, such as cyclophosphamide, work by causing cross-linking in DNA. However, they can also cause haemorrhagic cystitis, myelosuppression, and transitional cell carcinoma. Cytotoxic antibiotics, like bleomycin and anthracyclines, degrade preformed DNA and stabilize DNA-topoisomerase II complex, respectively. However, they can also cause lung fibrosis and cardiomyopathy. Antimetabolites, such as methotrexate and fluorouracil, inhibit dihydrofolate reductase and thymidylate synthesis, respectively. However, they can also cause myelosuppression, mucositis, and liver or lung fibrosis. Drugs that act on microtubules, like vincristine and docetaxel, inhibit the formation of microtubules and prevent microtubule depolymerisation & disassembly, respectively. However, they can also cause peripheral neuropathy, myelosuppression, and paralytic ileus. Topoisomerase inhibitors, like irinotecan, inhibit topoisomerase I, which prevents relaxation of supercoiled DNA. However, they can also cause myelosuppression. Other cytotoxic drugs, such as cisplatin and hydroxyurea, cause cross-linking in DNA and inhibit ribonucleotide reductase, respectively. However, they can also cause ototoxicity, peripheral neuropathy, hypomagnesaemia, and myelosuppression.

The ovarian vessels directly branch from the aorta to supply ovarian tumours. Meanwhile, the internal and external iliac nodes are responsible for draining the cervix.

Para-aortic Lymphadenopathy and its Association with Metastasis

Para-aortic lymphadenopathy is a condition where the lymph nodes located near the aorta become enlarged due to the spread of cancer cells. This condition is commonly associated with the metastasis of cancer cells from various organs, including the testis, ovary, and uterine fundus. In these cases, the cancer cells spread to the para-aortic lymph nodes at an early stage of the disease.

However, it is important to note that para-aortic nodal disease may also occur as a result of cancer cells spreading from other organs. In these cases, the para-aortic nodal disease represents a much later stage of the disease, as other nodal stations are involved earlier.

Overall, para-aortic lymphadenopathy is a significant concern for individuals with cancer, as it can indicate the spread of cancer cells to other parts of the body. Early detection and treatment of para-aortic nodal disease can improve the chances of successful treatment and recovery.

As long as the patient’s Hb level is 7 or higher, transfusion may not be necessary for their management. However, this threshold may vary depending on individual factors such as co-existing medical conditions. It is important to avoid using old blood during massive transfusions as its effectiveness may be compromised.

Blood Products and Cell Saver Devices

Blood products are essential in various medical procedures, especially in cases where patients require transfusions due to anaemia or bleeding. Packed red cells, platelet-rich plasma, platelet concentrate, fresh frozen plasma, and cryoprecipitate are some of the commonly used whole blood fractions. Fresh frozen plasma is usually administered to patients with clotting deficiencies, while cryoprecipitate is a rich source of Factor VIII and fibrinogen. Cross-matching is necessary for all blood products, and cell saver devices are used to collect and re-infuse a patient’s own blood lost during surgery.

Cell saver devices come in two types, those that wash the blood cells before re-infusion and those that do not. The former is more expensive and complicated to operate but reduces the risk of re-infusing contaminated blood. The latter avoids the use of donor blood and may be acceptable to Jehovah’s witnesses. However, it is contraindicated in malignant diseases due to the risk of facilitating disease dissemination.

In some surgical patients, the use of warfarin can pose specific problems and may require the use of specialised blood products. Warfarin reversal can be achieved through the administration of vitamin K, fresh frozen plasma, or human prothrombin complex. Fresh frozen plasma is used less commonly now as a first-line warfarin reversal, and human prothrombin complex is preferred due to its rapid action. However, it should be given with vitamin K as factor 6 has a short half-life.

Platelets, also known as thrombocytes, are derived from myeloid stem cells, similar to red blood cells. The process involves the development of a megakaryocyte from a common myeloid progenitor cell. Megakaryocytes are large cells with multilobulated nuclei that grow to become massive before breaking up to form platelets.

The primary signal responsible for megakaryocyte and platelet production is thrombopoietin.

Erythropoietin initiates the signal for red blood cell production, while granulocyte-colony stimulating factor stimulates the bone marrow to produce granulocytes. Interleukin-5 is a cytokine that stimulates the proliferation and activation of eosinophils.

Haematopoiesis: The Generation of Immune Cells

Haematopoiesis is the process by which immune cells are produced from haematopoietic stem cells in the bone marrow. These stem cells give rise to two main types of progenitor cells: myeloid and lymphoid progenitor cells. All immune cells are derived from these progenitor cells.

The myeloid progenitor cells generate cells such as macrophages/monocytes, dendritic cells, neutrophils, eosinophils, basophils, and mast cells. On the other hand, lymphoid progenitor cells give rise to T cells, NK cells, B cells, and dendritic cells.

This process is essential for the proper functioning of the immune system. Without haematopoiesis, the body would not be able to produce the necessary immune cells to fight off infections and diseases. Understanding haematopoiesis is crucial in developing treatments for diseases that affect the immune system.

Ipilimumab is a type of immune checkpoint inhibitor that is used to treat melanoma by blocking CTLA-4. Other immune checkpoint inhibitors, such as nivolumab and pembrolizumab, block PD-1 and can be used to treat various cancers including melanoma, Hodgkin’s lymphoma, and non-small cell lung cancer. Atezolizumab and durvalumab are examples of immune checkpoint inhibitors that block PD-L1 and can be used to treat lung and urothelial cancer. Alkylating agents like cyclophosphamide exert their effect by cross-linking DNA, while medications like vincristine and vinblastine inhibit the formation of microtubules.

Understanding Immune Checkpoint Inhibitors

Immune checkpoint inhibitors are a type of immunotherapy that is becoming increasingly popular in the treatment of certain types of cancer. Unlike traditional therapies such as chemotherapy, these targeted treatments work by harnessing the body’s natural anti-cancer immune response. They boost the immune system’s ability to attack and destroy cancer cells, rather than directly affecting their growth and proliferation.

T-cells are an essential part of our immune system that helps destroy cancer cells. However, some cancer cells produce high levels of proteins that turn T-cells off. Checkpoint inhibitors block this process and reactivate and increase the body’s T-cell population, enhancing the immune system’s ability to recognize and fight cancer cells.

There are different types of immune checkpoint inhibitors, including Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, and Durvalumab. These drugs block specific proteins found on T-cells and cancer cells, such as CTLA-4, PD-1, and PD-L1. They are administered by injection or intravenous infusion and can be given as a single-agent treatment or combined with chemotherapy or each other.

However, the mechanism of action of these drugs can result in side effects termed ‘Immune-related adverse events’ that are inflammatory and autoimmune in nature. This is because all immune cells are boosted by these drugs, not just the ones that target cancer. The overactive T-cells can produce side effects such as dry, itchy skin and rashes, nausea and vomiting, decreased appetite, diarrhea, tiredness and fatigue, shortness of breath, and a dry cough. Management of such side effects reflects the inflammatory nature, often involving corticosteroids. It is important to monitor liver, kidney, and thyroid function as these drugs can affect these organs.

In conclusion, the early success of immune checkpoint inhibitors in solid tumors has generated tremendous interest in further developing and exploring these strategies across the oncology disease spectrum. Ongoing testing in clinical trials creates new hope for patients affected by other types of disease.

Iron deficiency anaemia is a prevalent condition worldwide, with preschool-age children being the most affected. The lack of iron in the body leads to a decrease in red blood cells and haemoglobin, resulting in anaemia. The primary causes of iron deficiency anaemia are excessive blood loss, inadequate dietary intake, poor intestinal absorption, and increased iron requirements. Menorrhagia is the most common cause of blood loss in pre-menopausal women, while gastrointestinal bleeding is the most common cause in men and postmenopausal women. Vegans and vegetarians are more likely to develop iron deficiency anaemia due to the lack of meat in their diet. Coeliac disease and other conditions affecting the small intestine can prevent sufficient iron absorption. Children and pregnant women have increased iron demands, and the latter may experience dilution due to an increase in plasma volume.

The symptoms of iron deficiency anaemia include fatigue, shortness of breath on exertion, palpitations, pallor, nail changes, hair loss, atrophic glossitis, post-cricoid webs, and angular stomatitis. To diagnose iron deficiency anaemia, a full blood count, serum ferritin, total iron-binding capacity, transferrin, and blood film tests are performed. Endoscopy may be necessary to rule out malignancy, especially in males and postmenopausal females with unexplained iron-deficiency anaemia.

The management of iron deficiency anaemia involves identifying and treating the underlying cause. Oral ferrous sulfate is commonly prescribed, and patients should continue taking iron supplements for three months after the iron deficiency has been corrected to replenish iron stores. Iron-rich foods such as dark-green leafy vegetables, meat, and iron-fortified bread can also help. It is crucial to exclude malignancy by taking an adequate history and appropriate investigations if warranted.

JAK2 Mutation and Primary Polycythaemia

Polycythaemia is a condition characterized by an increase in the number of red blood cells in the body. In primary polycythaemia, over 95% of cases are associated with a mutation in the JAK2 pathway. This mutation causes the pathway to be constantly active, leading to the production of red blood cells even in the absence of erythropoietin (EPO). The most common mutation occurs in exon 12, affecting position V617F.

On the other hand, secondary causes of polycythaemia include COPD and smoking, which lower blood oxygenation and trigger the secretion of EPO by the kidney’s peritubular cells. ADPKD also promotes the secretion of increased EPO, resulting in the production and release of more red blood cells. Dehydration, on the other hand, reduces plasma volume, leading to an apparent/relative polycythaemia. While these factors can cause an increase in red blood cells, they are not associated with a primary haematological disorder like the JAK2 mutation.

Understanding Sickle-Cell Anaemia

Sickle-cell anaemia is a genetic disorder that occurs when an abnormal haemoglobin chain, known as HbS, is synthesized due to an autosomal recessive condition. This condition is more common in people of African descent, as the heterozygous condition offers some protection against malaria. In the UK, around 10% of Afro-Caribbean individuals are carriers of HbS. Symptoms in homozygotes typically do not develop until 4-6 months when the abnormal HbSS molecules take over from fetal haemoglobin.

The pathophysiology of sickle-cell anaemia involves the substitution of the polar amino acid glutamate with the non-polar valine in each of the two beta chains (codon 6) of haemoglobin. This substitution decreases the water solubility of deoxy-Hb, causing HbS molecules to polymerize and sickle in the deoxygenated state. HbAS patients sickle at p02 2.5 – 4 kPa, while HbSS patients sickle at p02 5 – 6 kPa. Sickle cells are fragile and can cause haemolysis, block small blood vessels, and lead to infarction.

To diagnose sickle-cell anaemia, haemoglobin electrophoresis is the definitive test. It is essential to understand the pathophysiology and symptoms of sickle-cell anaemia to provide appropriate care and management for affected individuals.

To divide the breast into four quadrants, one can visualize a vertical and horizontal line passing through the nipple. The superior lateral quadrant is where breast malignancies are most frequently detected. During a breast examination, it is crucial to palpate all quadrants and the axillary tail (which is part of the superior lateral quadrant). The quadrants also play a significant role in lymphatic drainage, as the medial quadrants can drain to the opposite side.

Breast Cancer Pathology: Understanding the Histological Features

Breast cancer pathology involves examining the histological features of the cancer cells to determine the underlying diagnosis. The invasive component of breast cancer is typically made up of ductal cells, although invasive lobular cancer may also occur. In situ lesions, such as DCIS, may also be present.

When examining breast cancer pathology, several typical changes are seen in conjunction with invasive breast cancer. These include nuclear pleomorphism, coarse chromatin, angiogenesis, invasion of the basement membrane, dystrophic calcification (which may be seen on mammography), abnormal mitoses, vascular invasion, and lymph node metastasis.

To grade the primary tumor, a scale of 1-3 is used, with 1 being the most benign lesion and 3 being the most poorly differentiated. Immunohistochemistry for estrogen receptor and herceptin status is routinely performed to further understand the cancer’s characteristics.

The grade, lymph node stage, and size are combined to provide the Nottingham prognostic index, which helps predict the patient’s prognosis and guide treatment decisions. Understanding the histological features of breast cancer is crucial in determining the best course of treatment for patients.

GVHD occurs when T cells from the donor tissue attack the recipient’s cells. This often manifests as skin and gastrointestinal symptoms in a host who lacks T cells, following a bone marrow or stem cell transplant. The immune response is initiated by donor CD4+ T cells recognizing the recipient’s MHC II as foreign, while donor CD8+ T cells cause tissue damage.

Understanding Graft Versus Host Disease

Graft versus host disease (GVHD) is a complication that can occur after bone marrow or solid organ transplantation. It happens when the T cells in the donor tissue attack the recipient’s cells. This is different from transplant rejection, where the recipient’s immune cells attack the donor tissue. GVHD is diagnosed using the Billingham criteria, which require that the transplanted tissue contains functioning immune cells, the donor and recipient are immunologically different, and the recipient is immunocompromised.

The incidence of GVHD varies, but it can occur in up to 50% of patients who receive allogeneic bone marrow transplants. Risk factors include poorly matched donor and recipient, the type of conditioning used before transplantation, gender disparity between donor and recipient, and the source of the graft.

Acute and chronic GVHD are considered separate syndromes. Acute GVHD typically occurs within 100 days of transplantation and affects the skin, liver, and gastrointestinal tract. Chronic GVHD may occur after acute disease or arise de novo and has a more varied clinical picture.

Diagnosis of GVHD is largely clinical and based on the exclusion of other pathology. Signs and symptoms of acute GVHD include a painful rash, jaundice, diarrhea, nausea, vomiting, and fever. Chronic GVHD can affect the skin, eyes, gastrointestinal tract, and lungs.

Treatment of GVHD involves immunosuppression and supportive measures. Intravenous steroids are the mainstay of treatment for severe cases of acute GVHD, while extended courses of steroid therapy are often needed in chronic GVHD. Second-line therapies include anti-TNF, mTOR inhibitors, and extracorporeal photopheresis. Topical steroid therapy may be sufficient in mild disease with limited cutaneous involvement. However, excessive immunosuppression may increase the risk of infection and limit the beneficial graft-versus-tumor effect of the transplant.

The lymphatic system of the breast is responsible for draining excess fluid and waste products. Lymph from the upper outer quadrant of the breast drains to the axillary lymph nodes, while lymph from the inner quadrants drains to the parasternal lymph nodes. Additionally, some lymph from the lower quadrants drains to the inferior phrenic lymph nodes.

Lymphatic drainage is the process by which lymphatic vessels carry lymph, a clear fluid containing white blood cells, away from tissues and organs and towards lymph nodes. The lymphatic vessels that drain the skin and follow venous drainage are called superficial lymphatic vessels, while those that drain internal organs and structures follow the arteries and are called deep lymphatic vessels. These vessels eventually lead to lymph nodes, which filter and remove harmful substances from the lymph before it is returned to the bloodstream.

The lymphatic system is divided into two main ducts: the right lymphatic duct and the thoracic duct. The right lymphatic duct drains the right side of the head and right arm, while the thoracic duct drains everything else. Both ducts eventually drain into the venous system.

Different areas of the body have specific primary lymph node drainage sites. For example, the superficial inguinal lymph nodes drain the anal canal below the pectinate line, perineum, skin of the thigh, penis, scrotum, and vagina. The deep inguinal lymph nodes drain the glans penis, while the para-aortic lymph nodes drain the testes, ovaries, kidney, and adrenal gland. The axillary lymph nodes drain the lateral breast and upper limb, while the internal iliac lymph nodes drain the anal canal above the pectinate line, lower part of the rectum, and pelvic structures including the cervix and inferior part of the uterus. The superior mesenteric lymph nodes drain the duodenum and jejunum, while the inferior mesenteric lymph nodes drain the descending colon, sigmoid colon, and upper part of the rectum. Finally, the coeliac lymph nodes drain the stomach.

Apixaban is a medication that directly inhibits factor Xa, which is responsible for the conversion of prothrombin to thrombin in the coagulation cascade. It is used as prophylaxis against embolic events in patients with atrial fibrillation, who are at increased risk due to blood pooling in the atria and potential clot formation. Unlike heparin, which activates antithrombin III to reduce blood clotting, apixaban works independently of antithrombin III. It also does not directly inhibit thrombin, which is the mechanism of action of dabigatran. Antiplatelets, such as aspirin and clopidogrel, work to decrease platelet activation and aggregation, but are not recommended for reducing the risks of embolic events in AF. Apixaban also does not inhibit vitamin K, which is the mechanism of action of warfarin.

Direct oral anticoagulants (DOACs) are medications used to prevent stroke in non-valvular atrial fibrillation (AF), as well as for the prevention and treatment of venous thromboembolism (VTE). To be prescribed DOACs for stroke prevention, patients must have certain risk factors, such as a prior stroke or transient ischaemic attack, age 75 or older, hypertension, diabetes mellitus, or heart failure. There are four DOACs available, each with a different mechanism of action and method of excretion. Dabigatran is a direct thrombin inhibitor, while rivaroxaban, apixaban, and edoxaban are direct factor Xa inhibitors. The majority of DOACs are excreted either through the kidneys or the liver, with the exception of apixaban and edoxaban, which are excreted through the feces. Reversal agents are available for dabigatran and rivaroxaban, but not for apixaban or edoxaban.

Massive splenomegaly can be a symptom of chronic myeloid leukaemia (CML), which is the known diagnosis of this woman. Left-sided swelling, increased tendency to bruise or bleed, and abdominal pain may also be present. However, a duodenal ulcer is more likely to cause indigestion and is not commonly associated with CML. While hepatomegaly may occur in CML, it is less common and less marked than splenomegaly. Large bowel obstruction is not typically associated with CML, but may be a presenting symptom of undiagnosed colorectal cancer. Although splenic rupture can cause abdominal pain, it is more likely to lead to an acute presentation due to complications of acute intra-abdominal bleeding.

Understanding Chronic Myeloid Leukaemia and its Management

Chronic myeloid leukaemia (CML) is a type of cancer that affects the blood and bone marrow. It is characterized by the presence of the Philadelphia chromosome in more than 95% of patients. This chromosome is formed due to a translocation between chromosomes 9 and 22, resulting in the fusion of the ABL proto-oncogene and the BCR gene. The resulting BCR-ABL gene produces a fusion protein that has excessive tyrosine kinase activity.

CML typically affects individuals between the ages of 60-70 years and presents with symptoms such as anaemia, weight loss, sweating, and splenomegaly. The condition is also associated with an increase in granulocytes at different stages of maturation and thrombocytosis. In some cases, CML may undergo blast transformation, leading to acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL).

The management of CML involves various treatment options, including imatinib, which is considered the first-line treatment. Imatinib is an inhibitor of the tyrosine kinase associated with the BCR-ABL defect and has a very high response rate in chronic phase CML. Other treatment options include hydroxyurea, interferon-alpha, and allogeneic bone marrow transplant. With proper management, individuals with CML can lead a normal life.

The patient is exhibiting symptoms of anaemia and low platelets, as evidenced by their pallor and bruising. Their blood tests indicate low levels of neutrophils, but normal levels of white cells. This suggests that there may be an issue with the patient’s common myeloid progenitor cells, as neutrophils, erythrocytes, and platelets all originate from this lineage. Therefore, options 1, 3, and 5 are incorrect, as they involve cancers that affect the lymphoid lineage. Acute myeloid leukaemia can cause low levels of myeloid cells due to a differentiation block, while chronic myeloid leukaemia can cause elevated neutrophil levels as it does not exhibit a differentiation block.

Haematopoiesis: The Generation of Immune Cells

Haematopoiesis is the process by which immune cells are produced from haematopoietic stem cells in the bone marrow. These stem cells give rise to two main types of progenitor cells: myeloid and lymphoid progenitor cells. All immune cells are derived from these progenitor cells.

The myeloid progenitor cells generate cells such as macrophages/monocytes, dendritic cells, neutrophils, eosinophils, basophils, and mast cells. On the other hand, lymphoid progenitor cells give rise to T cells, NK cells, B cells, and dendritic cells.

This process is essential for the proper functioning of the immune system. Without haematopoiesis, the body would not be able to produce the necessary immune cells to fight off infections and diseases. Understanding haematopoiesis is crucial in developing treatments for diseases that affect the immune system.

Mast cells originate from common myeloid progenitor cells.

Haematopoiesis: The Generation of Immune Cells

Haematopoiesis is the process by which immune cells are produced from haematopoietic stem cells in the bone marrow. These stem cells give rise to two main types of progenitor cells: myeloid and lymphoid progenitor cells. All immune cells are derived from these progenitor cells.

The myeloid progenitor cells generate cells such as macrophages/monocytes, dendritic cells, neutrophils, eosinophils, basophils, and mast cells. On the other hand, lymphoid progenitor cells give rise to T cells, NK cells, B cells, and dendritic cells.

This process is essential for the proper functioning of the immune system. Without haematopoiesis, the body would not be able to produce the necessary immune cells to fight off infections and diseases. Understanding haematopoiesis is crucial in developing treatments for diseases that affect the immune system.

The prothrombin time (PT) is used to assess the extrinsic pathway of the clotting cascade, while the activated partial thromboplastin time (aPTT) is used to assess the intrinsic pathway. The thrombin time is used to assess fibrin formation. A 50:50 mixing study is used to determine if a prolonged PT or aPTT is due to factor deficiency or a factor inhibitor.

The Coagulation Cascade: Two Pathways to Fibrin Formation

The coagulation cascade is a complex process that leads to the formation of a blood clot. There are two pathways that can lead to fibrin formation: the intrinsic pathway and the extrinsic pathway. The intrinsic pathway involves components that are already present in the blood and has a minor role in clotting. It is initiated by subendothelial damage, such as collagen, which leads to the formation of the primary complex on collagen by high-molecular-weight kininogen (HMWK), prekallikrein, and Factor 12. This complex activates Factor 11, which in turn activates Factor 9. Factor 9, along with its co-factor Factor 8a, forms the tenase complex, which activates Factor 10.

The extrinsic pathway, on the other hand, requires tissue factor released by damaged tissue. This pathway is initiated by tissue damage, which leads to the binding of Factor 7 to tissue factor. This complex activates Factor 9, which works with Factor 8 to activate Factor 10. Both pathways converge at the common pathway, where activated Factor 10 causes the conversion of prothrombin to thrombin. Thrombin hydrolyses fibrinogen peptide bonds to form fibrin and also activates factor 8 to form links between fibrin molecules.

Finally, fibrinolysis occurs, which is the process of clot resorption. Plasminogen is converted to plasmin to facilitate this process. It is important to note that certain factors are involved in both pathways, such as Factor 10, and that some factors are vitamin K dependent, such as Factors 2, 7, 9, and 10. The intrinsic pathway can be assessed by measuring the activated partial thromboplastin time (APTT), while the extrinsic pathway can be assessed by measuring the prothrombin time (PT).

Having a malignancy increases the likelihood of developing pulmonary embolism, as all types of cancer are known to increase the risk of venous thromboembolism. However, bronchiectasis, despite causing breathlessness and haemoptysis, is less likely to result in an acute attack and is not a common risk factor for PE. Contrary to popular belief, individuals with a high BMI are more likely to develop blood clots than those with a low BMI. Finally, conditions 4 and 5 are not typically associated with an increased risk of pulmonary embolism.

Risk Factors for Venous Thromboembolism

Venous thromboembolism (VTE) is a condition where blood clots form in the veins, which can lead to serious complications such as pulmonary embolism (PE). While some common predisposing factors include malignancy, pregnancy, and the period following an operation, there are many other factors that can increase the risk of VTE. These include underlying conditions such as heart failure, thrombophilia, and nephrotic syndrome, as well as medication use such as the combined oral contraceptive pill and antipsychotics. It is important to note that around 40% of patients diagnosed with a PE have no major risk factors. Therefore, it is crucial to be aware of all potential risk factors and take appropriate measures to prevent VTE.

Rectal cancer that occurs below the pectinate line is known to spread to the superficial inguinal lymph nodes. This is because the superficial inguinal nodes are responsible for draining the lymphatic system of the rectum below the pectinate line, as well as the lower limbs, scrotum/vulva.

It is important to note that the inferior mesenteric nodes are not involved in this process, as they primarily drain the hindgut structures from the transverse colon down to the rectum. Similarly, the internal iliac nodes are not involved, as they drain the inferior portion of the rectum, the anal canal superior to the pectinate line, and the pelvic viscera.

Para-aortic nodes are also not involved in the spread of rectal cancer below the pectinate line, as this portion of the rectum does not drain directly to these nodes. Instead, the testes/ovaries drain directly into the para-aortic nodes. Finally, popliteal nodes are not involved, as they only provide lymphatic drainage for the legs.

Lymphatic drainage is the process by which lymphatic vessels carry lymph, a clear fluid containing white blood cells, away from tissues and organs and towards lymph nodes. The lymphatic vessels that drain the skin and follow venous drainage are called superficial lymphatic vessels, while those that drain internal organs and structures follow the arteries and are called deep lymphatic vessels. These vessels eventually lead to lymph nodes, which filter and remove harmful substances from the lymph before it is returned to the bloodstream.

The lymphatic system is divided into two main ducts: the right lymphatic duct and the thoracic duct. The right lymphatic duct drains the right side of the head and right arm, while the thoracic duct drains everything else. Both ducts eventually drain into the venous system.

Different areas of the body have specific primary lymph node drainage sites. For example, the superficial inguinal lymph nodes drain the anal canal below the pectinate line, perineum, skin of the thigh, penis, scrotum, and vagina. The deep inguinal lymph nodes drain the glans penis, while the para-aortic lymph nodes drain the testes, ovaries, kidney, and adrenal gland. The axillary lymph nodes drain the lateral breast and upper limb, while the internal iliac lymph nodes drain the anal canal above the pectinate line, lower part of the rectum, and pelvic structures including the cervix and inferior part of the uterus. The superior mesenteric lymph nodes drain the duodenum and jejunum, while the inferior mesenteric lymph nodes drain the descending colon, sigmoid colon, and upper part of the rectum. Finally, the coeliac lymph nodes drain the stomach.

In coeliac disease, the spleen may undergo atrophy and Howell-Jolly bodies may be observed in red blood cells. Histiocytosis X includes Letterer-Siwe disease, which involves the excessive growth of macrophages.

The Anatomy and Function of the Spleen

The spleen is an organ located in the left upper quadrant of the abdomen. Its size can vary depending on the amount of blood it contains, but the typical adult spleen is 12.5cm long and 7.5cm wide, with a weight of 150g. The spleen is almost entirely covered by peritoneum and is separated from the 9th, 10th, and 11th ribs by both diaphragm and pleural cavity. Its shape is influenced by the state of the colon and stomach, with gastric distension causing it to resemble an orange segment and colonic distension causing it to become more tetrahedral.

The spleen has two folds of peritoneum that connect it to the posterior abdominal wall and stomach: the lienorenal ligament and gastrosplenic ligament. The lienorenal ligament contains the splenic vessels, while the short gastric and left gastroepiploic branches of the splenic artery pass through the layers of the gastrosplenic ligament. The spleen is in contact with the phrenicocolic ligament laterally.

The spleen has two main functions: filtration and immunity. It filters abnormal blood cells and foreign bodies such as bacteria, and produces properdin and tuftsin, which help target fungi and bacteria for phagocytosis. The spleen also stores 40% of platelets, reutilizes iron, and stores monocytes. Disorders of the spleen include massive splenomegaly, myelofibrosis, chronic myeloid leukemia, visceral leishmaniasis, malaria, Gaucher’s syndrome, portal hypertension, lymphoproliferative disease, haemolytic anaemia, infection, infective endocarditis, sickle-cell, thalassaemia, and rheumatoid arthritis.

Phagocytosis is facilitated by opsonisation, which involves coating the micro-organism with antibody, C3b, and specific acute phase proteins. This leads to an increase in phagocytic cell surface receptors on macrophages and neutrophils, which is mediated by pro-inflammatory cytokines. As a result, these cells are able to engulf the micro-organism.

Phagocytosis: The Process of Cell Ingestion

Phagocytosis is the process by which cells ingest foreign materials or pathogens. The first step in this process is opsonisation, where the organism is coated by an antibody. The second step is adhesion to the cell surface, followed by pseudopodial extension to form a phagocytic vacuole. Finally, lysosomes fuse with the vacuole and degrade its contents.

Phagocytosis is an essential process for the immune system to fight off infections and diseases. It is a complex process that involves multiple steps, including opsonisation, adhesion, and pseudopodial extension. The end result is the degradation of the foreign material or pathogen by lysosomes. Understanding the process of phagocytosis is crucial for developing treatments for diseases that involve the immune system.

The Factor V Leiden mutation causes activated protein C resistance, resulting in excess clotting due to inefficient inactivation of factor V. This is the correct answer.

Antiphospholipid antibodies binding to plasma membranes is not the correct answer as it is a mechanism of blood clot formation in antiphospholipid syndrome (APS).

High levels of platelets in the blood is also not the correct answer as it is not implicated in Factor V Leiden. Thrombocytosis, or high levels of platelets, can lead to clots but is not related to this mutation.

Low levels of factor V in the blood is also not the correct answer as factor V deficiency is a rare inherited bleeding disorder, not a clotting disorder. It is a form of haemophilia.

Understanding Factor V Leiden

Factor V Leiden is a common inherited thrombophilia, affecting around 5% of the UK population. It is caused by a mutation in the Factor V Leiden protein, resulting in activated factor V being inactivated 10 times more slowly by activated protein C than normal. This leads to activated protein C resistance, which increases the risk of venous thrombosis. Heterozygotes have a 4-5 fold risk of venous thrombosis, while homozygotes have a 10 fold risk, although the prevalence of homozygotes is much lower at 0.05%.

Despite its prevalence, screening for Factor V Leiden is not recommended, even after a venous thromboembolism. This is because a previous thromboembolism itself is a risk factor for further events, and specific management should be based on this rather than the particular thrombophilia identified.

Other inherited thrombophilias include Prothrombin gene mutation, Protein C deficiency, Protein S deficiency, and Antithrombin III deficiency. The table below shows the prevalence and relative risk of venous thromboembolism for each of these conditions.

Overall, understanding Factor V Leiden and other inherited thrombophilias can help healthcare professionals identify individuals at higher risk of venous thrombosis and provide appropriate management to prevent future events.

Condition | Prevalence | Relative risk of VTE
— | — | —
Factor V Leiden (heterozygous) | 5% | 4
Factor V Leiden (homozygous) | 0.05% | 10
Prothrombin gene mutation (heterozygous) | 1.5% | 3
Protein C deficiency | 0.3% | 10
Protein S deficiency | 0.1% | 5-10
Antithrombin III deficiency | 0.02% | 10-20

Understanding Antithrombin III Deficiency

Antithrombin III deficiency is a genetic condition that affects approximately 1 in 3,000 people. It is inherited in an autosomal dominant manner. This condition occurs when the body does not produce enough antithrombin III, a protein that helps to prevent blood clots by inhibiting certain clotting factors. Some patients with this deficiency have a shortage of normal antithrombin III, while others produce abnormal antithrombin III.

People with antithrombin III deficiency are at an increased risk of developing recurrent venous thromboses, which are blood clots that form in the veins. While arterial thromboses can also occur, they are less common. To manage this condition, patients may need to take warfarin for the rest of their lives to prevent thromboembolic events. During pregnancy, heparin may be used instead. Antithrombin III concentrates may also be used during surgery or childbirth.

It is important to note that patients with antithrombin III deficiency have a degree of resistance to heparin, so anti-Xa levels should be monitored carefully to ensure adequate anticoagulation. Compared to other inherited thrombophilias, antithrombin III deficiency is less common but has a higher relative risk of venous thromboembolism. Understanding this condition and its management is crucial for those affected and their healthcare providers.

G6PD deficiency is a genetic disorder that affects the production of glucose-6-phosphate dehydrogenase, which is necessary for the production of NADPH. NADPH is essential for maintaining glutathione, which helps prevent oxidative damage by neutralizing free radicals. Patients with G6PD deficiency have low levels of glutathione, making them more susceptible to oxidative stress and resulting in the destruction of red blood cells. This destruction leads to an enlarged spleen and jaundice, as bilirubin is released during the breakdown of hemoglobin. The patient’s Mediterranean descent and family history of the disease suggest G6PD deficiency, which was confirmed by a G6PD enzyme assay. The presence of Heinz bodies on blood film is also characteristic of the disease. The suggestion of an autosomal dominant defect of red cells is incorrect, as this is the pathophysiology for hereditary spherocytosis, which has different clinical features and would be seen on blood film.

Understanding G6PD Deficiency

G6PD deficiency is a common red blood cell enzyme defect that is inherited in an X-linked recessive fashion and is more prevalent in people from the Mediterranean and Africa. The deficiency can be triggered by many drugs, infections, and broad (fava) beans, leading to a crisis. G6PD is the first step in the pentose phosphate pathway, which converts glucose-6-phosphate to 6-phosphogluconolactone and results in the production of nicotinamide adenine dinucleotide phosphate (NADPH). NADPH is essential for converting oxidized glutathione back to its reduced form, which protects red blood cells from oxidative damage by oxidants such as superoxide anion (O2-) and hydrogen peroxide. Reduced G6PD activity leads to decreased reduced glutathione and increased red cell susceptibility to oxidative stress, resulting in neonatal jaundice, intravascular hemolysis, gallstones, splenomegaly, and the presence of Heinz bodies on blood films. Diagnosis is made by using a G6PD enzyme assay, and some drugs are known to cause hemolysis, while others are considered safe.

Compared to hereditary spherocytosis, G6PD deficiency is more common in males of African and Mediterranean descent and is characterized by neonatal jaundice, infection/drug-induced hemolysis, and gallstones. On the other hand, hereditary spherocytosis affects both males and females of Northern European descent and is associated with chronic symptoms, spherocytes on blood films, and the presence of erythrocyte membrane protein band 4.2 (EMA) binding.

Cytotoxic agents are drugs that are used to kill cancer cells. There are several types of cytotoxic agents, each with their own mechanism of action and potential adverse effects. Alkylating agents, such as cyclophosphamide, work by causing cross-linking in DNA. However, they can also cause haemorrhagic cystitis, myelosuppression, and transitional cell carcinoma. Cytotoxic antibiotics, like bleomycin and anthracyclines, degrade preformed DNA and stabilize DNA-topoisomerase II complex, respectively. However, they can also cause lung fibrosis and cardiomyopathy. Antimetabolites, such as methotrexate and fluorouracil, inhibit dihydrofolate reductase and thymidylate synthesis, respectively. However, they can also cause myelosuppression, mucositis, and liver or lung fibrosis. Drugs that act on microtubules, like vincristine and docetaxel, inhibit the formation of microtubules and prevent microtubule depolymerisation & disassembly, respectively. However, they can also cause peripheral neuropathy, myelosuppression, and paralytic ileus. Topoisomerase inhibitors, like irinotecan, inhibit topoisomerase I, which prevents relaxation of supercoiled DNA. However, they can also cause myelosuppression. Other cytotoxic drugs, such as cisplatin and hydroxyurea, cause cross-linking in DNA and inhibit ribonucleotide reductase, respectively. However, they can also cause ototoxicity, peripheral neuropathy, hypomagnesaemia, and myelosuppression.

Rivaroxaban is a direct inhibitor of factor Xa, which is the correct answer. Pulmonary emboli can be caused by various factors, and symptoms include chest pain, dyspnoea, and haemoptysis. Factor Xa inhibitors, such as rivaroxaban, have replaced warfarin as the first-line treatment for stroke prevention in patients with atrial fibrillation.

Dabigatran is a direct thrombin inhibitor and has a different mechanism of action compared to rivaroxaban. It is commonly used for venous thromboembolism prophylaxis after total knee or hip replacement surgery.

Dalteparin is a type of low molecular weight heparin (LMWH) and has a different mechanism of action compared to factor Xa inhibitors. It is used for prophylaxis against venous thromboembolism in patients who are immobile or have recently had surgery.

Fondaparinux is an indirect inhibitor of factor Xa and is not the correct answer. It is used for the treatment of deep-vein thrombosis, pulmonary embolism, and acute coronary syndrome.

Direct oral anticoagulants (DOACs) are medications used to prevent stroke in non-valvular atrial fibrillation (AF), as well as for the prevention and treatment of venous thromboembolism (VTE). To be prescribed DOACs for stroke prevention, patients must have certain risk factors, such as a prior stroke or transient ischaemic attack, age 75 or older, hypertension, diabetes mellitus, or heart failure. There are four DOACs available, each with a different mechanism of action and method of excretion. Dabigatran is a direct thrombin inhibitor, while rivaroxaban, apixaban, and edoxaban are direct factor Xa inhibitors. The majority of DOACs are excreted either through the kidneys or the liver, with the exception of apixaban and edoxaban, which are excreted through the feces. Reversal agents are available for dabigatran and rivaroxaban, but not for apixaban or edoxaban.

Understanding Chronic Myeloid Leukaemia and its Management

Chronic myeloid leukaemia (CML) is a type of cancer that affects the blood and bone marrow. It is characterized by the presence of the Philadelphia chromosome in more than 95% of patients. This chromosome is formed due to a translocation between chromosomes 9 and 22, resulting in the fusion of the ABL proto-oncogene and the BCR gene. The resulting BCR-ABL gene produces a fusion protein that has excessive tyrosine kinase activity.

CML typically affects individuals between the ages of 60-70 years and presents with symptoms such as anaemia, weight loss, sweating, and splenomegaly. The condition is also associated with an increase in granulocytes at different stages of maturation and thrombocytosis. In some cases, CML may undergo blast transformation, leading to acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL).

The management of CML involves various treatment options, including imatinib, which is considered the first-line treatment. Imatinib is an inhibitor of the tyrosine kinase associated with the BCR-ABL defect and has a very high response rate in chronic phase CML. Other treatment options include hydroxyurea, interferon-alpha, and allogenic bone marrow transplant. With proper management, individuals with CML can lead a normal life.

There are five potential disease phenotypes of alpha thalassaemia based on the number of faulty or missing globin alleles in a patient’s genotype. These include silent carrier (alpha(+) heterozygous) for one missing allele, alpha thalassaemia trait: alpha(0) heterozygous for two missing alleles, alpha thalassaemia trait: alpha(+) homozygous for two missing alleles, haemoglobin H disease for three missing alleles, and (–/–) for four missing alleles.

Understanding Alpha-Thalassaemia

Alpha-thalassaemia is a genetic disorder that results from a deficiency of alpha chains in haemoglobin. The condition is caused by a mutation in the alpha-globulin genes located on chromosome 16. The severity of the disease depends on the number of alpha globulin alleles affected. If one or two alleles are affected, the blood picture would be hypochromic and microcytic, but the haemoglobin level would typically be normal. However, if three alleles are affected, it results in a hypochromic microcytic anaemia with splenomegaly, which is known as Hb H disease. In the case of all four alleles being affected, which is known as homozygote, it can lead to death in utero, also known as hydrops fetalis or Bart’s hydrops. Understanding the different levels of severity of alpha-thalassaemia is crucial in diagnosing and managing the condition.

If a patient has a history of gastrectomy and is experiencing macrocytic anaemia, it is likely that they are suffering from B12 deficiency.

Vitamin B12 is essential for the development of red blood cells and the maintenance of the nervous system. It is absorbed through the binding of intrinsic factor, which is secreted by parietal cells in the stomach, and actively absorbed in the terminal ileum. A deficiency in vitamin B12 can be caused by pernicious anaemia, post gastrectomy, a vegan or poor diet, disorders or surgery of the terminal ileum, Crohn’s disease, or metformin use.

Symptoms of vitamin B12 deficiency include macrocytic anaemia, a sore tongue and mouth, neurological symptoms, and neuropsychiatric symptoms such as mood disturbances. The dorsal column is usually affected first, leading to joint position and vibration issues before distal paraesthesia.

Management of vitamin B12 deficiency involves administering 1 mg of IM hydroxocobalamin three times a week for two weeks, followed by once every three months if there is no neurological involvement. If a patient is also deficient in folic acid, it is important to treat the B12 deficiency first to avoid subacute combined degeneration of the cord.

The lymphatic drainage of the uterine fundus is similar to that of the ovaries, running alongside the ovarian vessels and draining into the para-aortic lymph nodes. Therefore, option 4 is correct. Options 1, 2, and 5 are incorrect as they refer to the drainage of the cervix and uterine body, which is different from that of the uterine fundus. Option 3 is also incorrect as the external iliac lymph nodes are not involved in the drainage of the uterine fundus.

Lymphatic Drainage of Female Reproductive Organs

The lymphatic drainage of the female reproductive organs is a complex system that involves multiple nodal stations. The ovaries drain to the para-aortic lymphatics via the gonadal vessels. The uterine fundus has a lymphatic drainage that runs with the ovarian vessels and may thus drain to the para-aortic nodes. Some drainage may also pass along the round ligament to the inguinal nodes. The body of the uterus drains through lymphatics contained within the broad ligament to the iliac lymph nodes. The cervix drains into three potential nodal stations; laterally through the broad ligament to the external iliac nodes, along the lymphatics of the uterosacral fold to the presacral nodes and posterolaterally along lymphatics lying alongside the uterine vessels to the internal iliac nodes. Understanding the lymphatic drainage of the female reproductive organs is important for the diagnosis and treatment of gynecological cancers.